Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 22

1.

Targeting TORC2 in multiple myeloma with a new mTOR kinase inhibitor.

Hoang B, Frost P, Shi Y, Belanger E, Benavides A, Pezeshkpour G, Cappia S, Guglielmelli T, Gera J, Lichtenstein A.

Blood. 2010 Nov 25;116(22):4560-8. doi: 10.1182/blood-2010-05-285726. Epub 2010 Aug 4.

2.

The mammalian target of rapamycin pathway as a therapeutic target in multiple myeloma.

Gera J, Lichtenstein A.

Leuk Lymphoma. 2011 Oct;52(10):1857-66. doi: 10.3109/10428194.2011.580478. Epub 2011 May 23. Review.

PMID:
21599581
3.

Target of rapamycin signaling in leukemia and lymphoma.

Vu C, Fruman DA.

Clin Cancer Res. 2010 Nov 15;16(22):5374-80. doi: 10.1158/1078-0432.CCR-10-0480. Epub 2010 Sep 8. Review.

4.

ATP-competitive inhibitors of mTOR: an update.

Schenone S, Brullo C, Musumeci F, Radi M, Botta M.

Curr Med Chem. 2011;18(20):2995-3014. Review.

PMID:
21651476
5.

mTOR kinase inhibitors as potential cancer therapeutic drugs.

Sun SY.

Cancer Lett. 2013 Oct 28;340(1):1-8. doi: 10.1016/j.canlet.2013.06.017. Epub 2013 Jun 20. Review.

6.

Evolutionarily conserved regulation of TOR signalling.

Takahara T, Maeda T.

J Biochem. 2013 Jul;154(1):1-10. doi: 10.1093/jb/mvt047. Epub 2013 May 21. Review.

PMID:
23698095
7.

Time now to TORC the TORC? New developments in mTOR pathway inhibition in lymphoid malignancies.

Eyre TA, Collins GP, Goldstone AH, Cwynarski K.

Br J Haematol. 2014 Aug;166(3):336-51. doi: 10.1111/bjh.12945. Epub 2014 May 19. Review.

PMID:
24842496
8.

New developments in mammalian target of rapamycin inhibitors for the treatment of sarcoma.

Agulnik M.

Cancer. 2012 Mar 15;118(6):1486-97. doi: 10.1002/cncr.26361. Epub 2011 Aug 11. Review.

9.

Next generation of mammalian target of rapamycin inhibitors for the treatment of cancer.

Nelson V, Altman JK, Platanias LC.

Expert Opin Investig Drugs. 2013 Jun;22(6):715-22. doi: 10.1517/13543784.2013.787066. Epub 2013 Apr 2. Review.

PMID:
23544840
10.

The mTOR signaling pathway is an emerging therapeutic target in multiple myeloma.

Li J, Zhu J, Cao B, Mao X.

Curr Pharm Des. 2014;20(1):125-35. Review.

PMID:
24001224
11.

Inhibitors of mTOR.

Kl├╝mpen HJ, Beijnen JH, Gurney H, Schellens JH.

Oncologist. 2010;15(12):1262-9. doi: 10.1634/theoncologist.2010-0196. Epub 2010 Dec 8. Review.

12.

Where is mTOR and what is it doing there?

Betz C, Hall MN.

J Cell Biol. 2013 Nov 25;203(4):563-74. doi: 10.1083/jcb.201306041. Review.

13.

The evolution of the TOR pathway and its role in cancer.

Beauchamp EM, Platanias LC.

Oncogene. 2013 Aug 22;32(34):3923-32. doi: 10.1038/onc.2012.567. Epub 2012 Dec 17. Review.

PMID:
23246968
14.

Current state of mTOR targeting in human breast cancer.

Wazir U, Wazir A, Khanzada ZS, Jiang WG, Sharma AK, Mokbel K.

Cancer Genomics Proteomics. 2014 Jul-Aug;11(4):167-74. Review.

PMID:
25048346
15.

mTOR in aging, metabolism, and cancer.

Cornu M, Albert V, Hall MN.

Curr Opin Genet Dev. 2013 Feb;23(1):53-62. doi: 10.1016/j.gde.2012.12.005. Epub 2013 Jan 11. Review.

PMID:
23317514
16.

mTOR Signalling in Health and Disease.

Proud CG.

Biochem Soc Trans. 2011 Apr;39(2):431-6. doi: 10.1042/BST0390431. Review.

PMID:
21428914
17.

TORC2 Structure and Function.

Gaubitz C, Prouteau M, Kusmider B, Loewith R.

Trends Biochem Sci. 2016 Jun;41(6):532-45. doi: 10.1016/j.tibs.2016.04.001. Epub 2016 May 5. Review.

PMID:
27161823
18.

Mammalian target of rapamycin signaling in diabetic cardiovascular disease.

Chong ZZ, Maiese K.

Cardiovasc Diabetol. 2012 Jul 16;11:45. doi: 10.1186/1475-2840-11-45. Review.

19.

Targeting mTOR for the treatment of AML. New agents and new directions.

Altman JK, Sassano A, Platanias LC.

Oncotarget. 2011 Jun;2(6):510-7. Review.

20.

Review series: TOR kinase complexes and cell migration.

Liu L, Parent CA.

J Cell Biol. 2011 Sep 19;194(6):815-24. doi: 10.1083/jcb.201102090. Review.

Items per page

Supplemental Content

Write to the Help Desk